|
Clinical narrative:
an impella cp was inserted via right femoral artery access in a male patient of undocumented age presenting with acute myocardial infarction and cardiogenic shock.The patient's clinical condition prior to support initiation was reported as scai shock stage e.Prior to impella cp implantation, the patient was receiving extracorporeal membrane oxygenation (ecmo) as the primary support modality, as well as inotropes, vasopressors, and respiratory support.The impella cp was utilized for left ventricular venting during ecmo support.One day after implantation, a purge cassette malfunction was identified when a purge occlusion alarm was displayed on the automated impella controller.The purge cassette was removed and replaced.Following replacement, purge pressure and purge flow returned to appropriate levels.There was no interruption in hemodynamic support and no reported patient injury related to the event.During the course of support, the treating team also expressed concerns for possible heparin-induced thrombocytopenia (hit).As a precaution, the purge solution was changed to sodium bicarbonate and systemic anticoagulation was transitioned to argatroban.Platelet count information sufficient to confirm the onset of hit were not reported.Throughout support, the device was reported to function as intended at performance level p-8 with a flow rate of 3.3 l/min using a purge solution of 5% dextrose in water with sodium bicarbonate.After 6 days of support, the impella cp was successfully weaned and explanted.Whether the patient remained on ecmo support was not reported.No additional intervention beyond purge cassette replacement and modification of anticoagulation management was required.There was no identified clinical adverse event identified with the purge event.
|
|
The device is available for return.This is one of two related reports.This report represents the impella cp and another report will be submitted to represent the purge cassette.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by abiomed inc, or its employees that the report constitutes an admission that the product, abiomed inc, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|